<DOC>
	<DOCNO>NCT00004863</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness paclitaxel GEM 231 treat patient recurrent refractory solid tumor .</brief_summary>
	<brief_title>Paclitaxel GEM 231 Treating Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety maximum tolerate dose GEM 231 paclitaxel patient recurrent refractory solid tumor . II . Determine preliminary antitumor activity regimen patient . OUTLINE : This dose escalation study GEM 231 . Patients receive paclitaxel IV 3 hour day 1 , immediately follow GEM 231 2 hour day 1 , 4 , 8 , 11 , 15 , 18 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat one two dos paclitaxel escalate dos GEM 231 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow monthly 3 month . PROJECTED ACCRUAL : A maximum 1 patient accrue per week study maximum tolerate dose reach .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor refractory standard therapy standard therapy exist Measurable evaluable disease No CNS metastases untreated , associated seizure , require intravenous medication and/or hospitalization PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.5 g/dL Hepatic : Bilirubin great upper limit normal ( ULN ) , except Gilbert 's syndrome ( great 1.5 time ULN liver metastasis present ) PT aPTT normal SGOT SGPT less 3 time ULN ( great 5 time ULN liver metastasis present ) Renal : Creatinine le 1.25 time ULN No renal tubular dysfunction ( i.e. , least 2+ proteinuria within past 2 week ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month prior , , 3 month study No serious medical condition would prevent compliance No serious infection No known hypersensitivity paclitaxel drug formulate Cremophor oligodeoxynucleotides Adequate venous access No psychological geographical condition would prevent compliance PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior transfusion Prior biologic therapy allow recovered No concurrent biologic therapy Chemotherapy : Prior chemotherapy allow recover No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy allow recovered Concurrent palliative hormonal therapy allow Radiotherapy : Prior radiotherapy allow recover No concurrent radiotherapy ( except palliative ) Surgery : At least 2 week since prior major surgery wound complication Other : At least 2 week since prior investigational drug No investigational drug within 28 day study No concurrent CYP3A metabolism dependent drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>